Index - P/E - EPS (ttm) -19.38 Insider Own 0.10% Shs Outstand 103.77M Perf Week -5.70%
Market Cap 23.69B Forward P/E - EPS next Y -9.23 Insider Trans -53.21% Shs Float 103.09M Perf Month -10.47%
Income -2003.80M PEG - EPS next Q -3.48 Inst Own 57.40% Short Float / Ratio 1.84% / 9.64 Perf Quarter 1.62%
Sales 1.42B P/S 16.73 EPS this Y -23.70% Inst Trans -0.43% Short Interest 1.89M Perf Half Y 30.46%
Book/sh 42.24 P/B 5.40 EPS next Y 29.90% ROA -28.10% Target Price 316.74 Perf Year 73.91%
Cash/sh 43.71 P/C 5.22 EPS next 5Y - ROE -39.60% 52W Range 124.46 - 280.62 Perf YTD 3.79%
Dividend - P/FCF - EPS past 5Y -55.10% ROI -37.20% 52W High -18.66% Beta 0.79
Dividend % - Quick Ratio 3.40 Sales past 5Y 42.80% Gross Margin 79.80% 52W Low 83.41% ATR 8.98
Employees 9200 Current Ratio 3.50 Sales Q/Q 77.60% Oper. Margin - RSI (14) 41.04 Volatility 4.28% 3.17%
Optionable Yes Debt/Eq 0.12 EPS Q/Q 30.90% Profit Margin - Rel Volume 1.06 Prev Close 236.90
Shortable Yes LT Debt/Eq 0.05 Earnings May 04 BMO Payout - Avg Volume 196.36K Price 228.27
Recom 1.70 SMA20 -6.46% SMA50 -5.08% SMA200 8.83% Volume 209,504 Change -3.64%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-12-23 Initiated Daiwa Securities
Buy
$308
Oct-13-22 Upgrade SVB Leerink
Mkt Perform → Outperform
$177 → $200
Oct-13-22 Upgrade Guggenheim
Neutral → Buy
$205
Aug-09-22 Resumed JP Morgan
Overweight
$296
Mar-17-22 Downgrade SVB Leerink
Outperform → Mkt Perform
$300 → $177
Feb-07-22 Initiated Deutsche Bank
Buy
Oct-12-21 Initiated Bernstein
Outperform
$431
Oct-06-21 Upgrade CLSA
Underperform → Buy
Mar-08-21 Initiated China Renaissance
Buy
Mar-01-21 Downgrade CLSA
Outperform → Underperform
$330 → $321
Nov-09-20 Downgrade Ladenburg Thalmann
Buy → Neutral
Nov-06-20 Downgrade Piper Sandler
Neutral → Underweight
$175 → $185
Nov-06-20 Downgrade Maxim Group
Buy → Hold
Jul-10-20 Downgrade CLSA
Buy → Outperform
Mar-13-20 Upgrade Macquarie
Underperform → Neutral
Feb-18-20 Resumed Goldman
Buy
Jan-17-20 Upgrade CLSA
Outperform → Buy
Jan-17-20 Resumed Morgan Stanley
Overweight
$210
Dec-16-19 Downgrade Piper Jaffray
Overweight → Neutral
Dec-16-19 Downgrade Guggenheim
Buy → Neutral
Show Previous Ratings
May-30-23 07:00AM 07:00AM May-25-23 05:05PM 02:45PM May-24-23 07:00AM
07:00AM
Loading…
May-17-23 07:00AM May-11-23 07:02AM May-09-23 09:29AM May-06-23 08:00AM May-05-23 06:01AM May-04-23 07:00AM Apr-28-23 01:39PM Apr-26-23 10:27AM Apr-25-23 08:45AM 07:00AM
01:50PM
Loading…
Apr-20-23 01:50PM 07:00AM Apr-19-23 07:22PM Apr-17-23 02:32PM 02:32PM 02:30PM 02:30PM 08:41AM Apr-14-23 02:45PM Apr-13-23 12:02PM (Investor's Business Daily)
10:45AM (Investor's Business Daily)
07:00AM Apr-10-23 03:07AM Apr-06-23 05:24PM Mar-30-23 07:00AM
06:25AM
Loading…
Mar-27-23 06:25AM Mar-25-23 02:53PM Mar-21-23 07:00AM Mar-17-23 12:26PM Mar-16-23 12:06PM Mar-13-23 05:30AM (South China Morning Post)
05:30AM (South China Morning Post)
Mar-08-23 12:36PM (Thomson Reuters StreetEvents)
Feb-28-23 11:54AM 09:35AM Feb-27-23 09:35AM 07:00AM Feb-26-23 08:04AM Feb-24-23 07:00AM 07:00AM Feb-23-23 08:34AM Feb-22-23 09:35AM Feb-15-23 09:40AM Feb-06-23 06:37AM Feb-03-23 07:00AM 05:53AM Feb-01-23 07:00AM Jan-20-23 01:00PM 06:22AM Jan-19-23 05:03PM 07:00AM Jan-18-23 05:32PM 08:27AM Jan-17-23 05:00PM Jan-16-23 08:50AM Jan-04-23 07:07AM Dec-30-22 09:00AM Dec-13-22 10:00AM Dec-09-22 07:00AM Dec-08-22 03:01PM (Investor's Business Daily)
02:10PM Dec-01-22 08:12AM Nov-27-22 08:39AM Nov-22-22 08:30AM Nov-17-22 07:00AM Nov-15-22 07:00AM Nov-10-22 07:00AM Nov-09-22 07:00AM Nov-04-22 07:00AM Nov-03-22 09:15AM 09:00AM Nov-02-22 07:00AM Oct-26-22 07:00AM Oct-17-22 12:31PM Oct-14-22 10:26AM 06:30AM Oct-13-22 11:08AM 10:14AM Oct-12-22 04:08PM (Investor's Business Daily) +20.55%
10:14AM 07:00AM Sep-29-22 02:31PM Sep-20-22 06:45AM Sep-19-22 07:01PM 07:00AM Sep-12-22 09:08AM Sep-10-22 02:30AM Sep-07-22 07:27PM Aug-28-22 06:34AM Aug-23-22 07:00AM Aug-15-22 07:24PM 07:00AM Aug-14-22 10:09AM Aug-09-22 06:00AM Aug-08-22 09:03AM
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Enlivex Therapeutics Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Wu Xiaobin President, COO & GM China May 08 Sale 253.72 7,000 1,776,037 0 May 10 04:44 PM Wang Xiaodong Chair, Scientific Advisory Brd Mar 08 Option Exercise 0.13 67,635 8,793 67,635 Mar 10 06:48 PM Wang Xiaodong Chair, Scientific Advisory Brd Mar 08 Sale 226.03 67,635 15,287,339 0 Mar 10 06:48 PM Wang Julia Aijun Chief Financial Officer Mar 01 Sale 240.21 343 82,392 0 Mar 03 05:00 PM Wang Xiaodong Chair, Scientific Advisory Brd Jan 12 Sale 260.52 5,000 1,302,585 0 Jan 17 05:13 PM Wang Xiaodong Chair, Scientific Advisory Brd Jan 11 Sale 252.66 2,500 631,647 0 Jan 11 04:50 PM OYLER JOHN Chief Executive Officer Jan 10 Sale 248.51 13,594 3,378,292 0 Jan 12 04:52 PM OYLER JOHN Chief Executive Officer Jan 10 Sale 248.52 6,797 1,689,157 0 Jan 12 04:52 PM Wang Xiaodong Chair, Scientific Advisory Brd Jan 10 Sale 250.09 1,600 400,152 0 Jan 11 04:50 PM Wang Xiaodong Chair, Scientific Advisory Brd Jan 09 Sale 250.00 900 225,000 0 Jan 11 04:50 PM OYLER JOHN Chief Executive Officer Dec 29 Sale 224.46 3,434 770,798 0 Dec 29 06:24 PM OYLER JOHN Chief Executive Officer Dec 29 Sale 224.46 1,716 385,174 0 Dec 29 06:24 PM OYLER JOHN Chief Executive Officer Dec 28 Sale 224.73 733 164,724 0 Dec 29 06:24 PM OYLER JOHN Chief Executive Officer Dec 28 Sale 224.73 367 82,474 0 Dec 29 06:24 PM OYLER JOHN Chief Executive Officer Dec 27 Sale 224.29 2,239 502,193 0 Dec 29 06:24 PM OYLER JOHN Chief Executive Officer Dec 27 Sale 224.29 1,120 251,209 0 Dec 29 06:24 PM Wang Xiaodong Chair, Scientific Advisory Brd Dec 13 Sale 211.33 3,013 636,723 0 Dec 15 05:04 PM OYLER JOHN Chief Executive Officer Nov 15 Sale 206.84 25,000 5,171,105 0 Nov 17 05:10 PM OYLER JOHN Chief Executive Officer Nov 15 Sale 206.82 4,928 1,019,229 0 Nov 17 05:10 PM Wang Xiaodong Chair, Scientific Advisory Brd Nov 15 Sale 210.14 1,987 417,541 0 Nov 17 05:13 PM OYLER JOHN Chief Executive Officer Sep 21 Sale 149.99 19,480 2,921,714 0 Sep 22 05:34 PM OYLER JOHN Chief Executive Officer Sep 20 Sale 153.50 30,520 4,684,842 0 Sep 22 05:34 PM Wang Julia Aijun Chief Financial Officer Jul 01 Sale 158.50 295 46,758 0 Jul 05 05:29 PM Wang Lai Global Head of R&D Jun 27 Sale 177.32 458 81,215 0 Jun 28 05:32 PM Wu Xiaobin President, COO & GM China Jun 21 Sale 144.36 1,010 145,804 0 Jun 22 05:45 PM Wang Lai Global Head of R&D Jun 21 Sale 149.01 723 107,734 0 Jun 22 05:47 PM Wu Xiaobin President, COO & GM China Jun 17 Sale 139.60 578 80,691 1,010 Jun 22 05:45 PM Wang Lai Global Head of R&D Jun 17 Sale 139.40 445 62,034 723 Jun 22 05:47 PM Wang Julia Aijun Chief Financial Officer Jun 17 Sale 136.64 161 21,999 0 Jun 21 05:09 PM Wu Xiaobin President, COO & GM China Jun 06 Sale 141.99 3,410 484,202 0 Jun 08 05:42 PM Wang Lai Global Head of R&D Jun 06 Sale 142.00 660 93,718 0 Jun 08 05:43 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
